Cargando…

Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown

This is a retrospective, multicenter study of consecutive patients with nAMD scheduled for a visit and/or a treatment with an intravitreal injection (IVI) during the 3 months before lockdown in the Ophthalmology Departments of six centers of Europe.The study was conducted on 546 patients, of which 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Arruabarrena, Carolina, Toro, Mario Damiano, Onen, Mehmet, Malyugin, Boris E, Rejdak, Robert, Tognetto, Danielle, Zweifel, Sandrine, Giglio, Rosa, Teus, Miguel A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348378/
https://www.ncbi.nlm.nih.gov/pubmed/34362066
http://dx.doi.org/10.3390/jcm10153281
_version_ 1783735325332340736
author Arruabarrena, Carolina
Toro, Mario Damiano
Onen, Mehmet
Malyugin, Boris E
Rejdak, Robert
Tognetto, Danielle
Zweifel, Sandrine
Giglio, Rosa
Teus, Miguel A
author_facet Arruabarrena, Carolina
Toro, Mario Damiano
Onen, Mehmet
Malyugin, Boris E
Rejdak, Robert
Tognetto, Danielle
Zweifel, Sandrine
Giglio, Rosa
Teus, Miguel A
author_sort Arruabarrena, Carolina
collection PubMed
description This is a retrospective, multicenter study of consecutive patients with nAMD scheduled for a visit and/or a treatment with an intravitreal injection (IVI) during the 3 months before lockdown in the Ophthalmology Departments of six centers of Europe.The study was conducted on 546 patients, of which 55.13% were females, almost 100% of the patients were White/Caucasian race, and 71.53% of the patients presented a type 1 macular neovascularization (NVM). A total of 62.82% of patients (343 patients) that were on scheduled clinic visits and/or intravitreal injection treatment during the 3 months before the quarantine did not attend either to visit or for treatment during the lockdown. The mean number of injections during the lockdown was significantly reduced. This was followed by a significant reduction in the mean best-corrected visual acuity (BCVA) between the 3 months before the lockdown (mean BCVA of 60.68 ± 19.77 letters) and 6 months after lockdown (mean BCVA of 56.98 ± 22.59 letters). Patients with better BCVA before the lockdown and the ones showing neovascular activity were more likely to attend their scheduled visits and/or IVI treatments. The COVID-19 pandemic and the lockdown have led to a decrease in the number of IVI treatments in patients with nAMD, evidencing a significant vision loss at 6 months.
format Online
Article
Text
id pubmed-8348378
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83483782021-08-08 Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown Arruabarrena, Carolina Toro, Mario Damiano Onen, Mehmet Malyugin, Boris E Rejdak, Robert Tognetto, Danielle Zweifel, Sandrine Giglio, Rosa Teus, Miguel A J Clin Med Article This is a retrospective, multicenter study of consecutive patients with nAMD scheduled for a visit and/or a treatment with an intravitreal injection (IVI) during the 3 months before lockdown in the Ophthalmology Departments of six centers of Europe.The study was conducted on 546 patients, of which 55.13% were females, almost 100% of the patients were White/Caucasian race, and 71.53% of the patients presented a type 1 macular neovascularization (NVM). A total of 62.82% of patients (343 patients) that were on scheduled clinic visits and/or intravitreal injection treatment during the 3 months before the quarantine did not attend either to visit or for treatment during the lockdown. The mean number of injections during the lockdown was significantly reduced. This was followed by a significant reduction in the mean best-corrected visual acuity (BCVA) between the 3 months before the lockdown (mean BCVA of 60.68 ± 19.77 letters) and 6 months after lockdown (mean BCVA of 56.98 ± 22.59 letters). Patients with better BCVA before the lockdown and the ones showing neovascular activity were more likely to attend their scheduled visits and/or IVI treatments. The COVID-19 pandemic and the lockdown have led to a decrease in the number of IVI treatments in patients with nAMD, evidencing a significant vision loss at 6 months. MDPI 2021-07-25 /pmc/articles/PMC8348378/ /pubmed/34362066 http://dx.doi.org/10.3390/jcm10153281 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Arruabarrena, Carolina
Toro, Mario Damiano
Onen, Mehmet
Malyugin, Boris E
Rejdak, Robert
Tognetto, Danielle
Zweifel, Sandrine
Giglio, Rosa
Teus, Miguel A
Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown
title Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown
title_full Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown
title_fullStr Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown
title_full_unstemmed Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown
title_short Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown
title_sort impact on visual acuity in neovascular age related macular degeneration (namd) in europe due to covid-19 pandemic lockdown
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348378/
https://www.ncbi.nlm.nih.gov/pubmed/34362066
http://dx.doi.org/10.3390/jcm10153281
work_keys_str_mv AT arruabarrenacarolina impactonvisualacuityinneovascularagerelatedmaculardegenerationnamdineuropeduetocovid19pandemiclockdown
AT toromariodamiano impactonvisualacuityinneovascularagerelatedmaculardegenerationnamdineuropeduetocovid19pandemiclockdown
AT onenmehmet impactonvisualacuityinneovascularagerelatedmaculardegenerationnamdineuropeduetocovid19pandemiclockdown
AT malyuginborise impactonvisualacuityinneovascularagerelatedmaculardegenerationnamdineuropeduetocovid19pandemiclockdown
AT rejdakrobert impactonvisualacuityinneovascularagerelatedmaculardegenerationnamdineuropeduetocovid19pandemiclockdown
AT tognettodanielle impactonvisualacuityinneovascularagerelatedmaculardegenerationnamdineuropeduetocovid19pandemiclockdown
AT zweifelsandrine impactonvisualacuityinneovascularagerelatedmaculardegenerationnamdineuropeduetocovid19pandemiclockdown
AT gigliorosa impactonvisualacuityinneovascularagerelatedmaculardegenerationnamdineuropeduetocovid19pandemiclockdown
AT teusmiguela impactonvisualacuityinneovascularagerelatedmaculardegenerationnamdineuropeduetocovid19pandemiclockdown